Studie I3Y-MC-JPCF/MonarchE Lilly

I3Y-MC-JPCF/MonarchE Lilly

MonarchE: Protocol I3Y-MC-JPCF A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Frauenklinik Frauenklinik Ismaninger Str. 22 81675 München Germany

III

Rekrutierung beendet

Positiv

2017-08-14

Unbekannt / Unbekannt

1

Chemo,Hormon - Therapieart: adjuvant